GoggleDocs

🥽🩺Docs/nurses/pharmacists from U.K. Talking CardioRenoMetabolic & more Catch us on YouTube |Educate, Motivate, Activate!

[GoggleDocs @GoggleDocs]

🔍 10% Visceral Fat loss⤵️ T2D cases by 28% over 10y

5- and 10-yr follow-up of two 18-mo lifestyle RCTs. The story isn’t the weight loss. It’s what stayed lost after the weight came back:

🔹 VAT -27% at 18 mo (MRI)
🔸 5–10 yr later: weight fully regained. VAT still ~15% below baseline (~55–60% of original loss preserved)
🔹 Each 10% VAT loss = 28% lower T2D risk in follow-up (HR 0.72). Association, not proof
🔸 Liver and pancreatic fat fully regained

Track waist, not just weight.

🔗 https://t.co/Hp8C0gHJxw

[GoggleDocs @GoggleDocs]

@parthaskar 💔 “Grief is the price we pay for love.” - Colin Murray Parkes. Thinking of you and your family.

[GoggleDocs @GoggleDocs]

@parthaskar @RCPhysicians @DrLKVaughan @DrAsifQasim @COPDdoc @respirologist @DrSelvarajah @DrSteveTaylor @doctor_katie @ShivaniM_KC @HamidIftikhar33 😳

[Partha S Kar 🇮🇳🇬🇧🏏🎥 @parthaskar]

The attempts of the @RCPhysicians to cling on to the vestiges of what they once supported is quite ...amazing

The requirements to be... Certificate in Geriatric Medicine Knowledge-Based Assessment Lead includes being a PA for 7 years.

I predict this is a degree anyone can do and be equated to specialist training in near future too.

@GeriSoc - are you saying a Consultant of 3 years experience and a PA of 7 years experience are at par?

Cos that's....something

Link:

https://t.co/67tFEl2NXM

[GoggleDocs @GoggleDocs]

🚨 TRIUMPH-1: #retatrutide topline data🚨
Phase 3, n=2,339, 80 wk, obesity without diabetes (efficacy estimand):
🔹 12 mg: -28.3% body weight (-31.9 kg)
🔸 9 mg: -25.9% | 4 mg: -19.0% | Placebo: -2.2%
🔹 ≥30% weight loss: 45.3% vs 0.5%
🔸 104-wk extension (BMI ≥35, n=532), 12 mg → MTD: -30.3%

Cross-trial context (obesity, no diabetes):
🔹 STEP-1 SEMA 2.4 mg, 68 wk: -14.9%
🔸 SURMOUNT-1 TZP 15 mg, 72 wk: -20.9% 🔹
TRIUMPH-1 RETA 12 mg, 80 wk: -28.3%

⚠️But:
🔸 Topline press release. No peer-reviewed publication yet
🔹 AE discontinuation at 12 mg: 11.3% vs 4.9% placebo
🔸 Dysesthesia 5.1–12.5% vs 0.9%.

Efficacy ceiling keeps moving. Enthusiasm needs caution. Still unlicensed in humans outside of research❗️
🔗 https://t.co/olGUBvpqua

[GoggleDocs @GoggleDocs]

To be honest there are a lot of unknowns about this. In terms of diabetic retinopathy the postulated theory remain rapid drop in glucose exacerbation the retinopathy. Although they are GLP-1 receptors within the retina.

In terms of normal glucose in an obese population without T2D less is known and particularly in non diabetic retinopathy. Other than what you have seen

[Partha S Kar 🇮🇳🇬🇧🏏🎥 @parthaskar]

Age of diagnosis; #T1Diabetes #T2Diabetes & science

“Clinicians should be aware that patients progressing to #insulin within 3 years of diagnosis have a high likelihood of #type1diabetes, regardless of initial diagnosis”

Via @DiabetologiaJnl

Please use, RT as possible

Link:

https://t.co/Qg6yf0L98y

[GoggleDocs @GoggleDocs]

The opportunity this provides and potential is there… if science builds further and regulation/policy/funding allows… hopefully will go the way of tech all those years ago …. Would like to get to a point to say the next 5 years is about cementing and implementing immunotherapy in T1D… not there yet though…

[Partha S Kar 🇮🇳🇬🇧🏏🎥 @parthaskar]

Some weekend reading for those interested in...science

For ever more?

Treatment of #T1Diabetes has relied on #Insulin

And the 'cure' is forever '10 years away'

Yet...what hope does science offer...what are the areas of intrigue and interest?

A fabulous article via @jclinicalinvest - and the vision of immune tolerance.

@ShivaniM_KC @DanielJDrucker @aaronjkowalski @BreakthroughT1D @BT1DUK @DiabetesUK

Link:

https://t.co/qyhDXjcVtr

[Partha S Kar 🇮🇳🇬🇧🏏🎥 @parthaskar]

Some early morning #Diabetes education on a Friday….

Why not.

“Is that HbA1c correct?”

Have a look at the wider picture 🙂

Use, RT as you wish

#T1D #T2D

[Cristina Tejera @cristinatejerap]

¿Cuándo elegir semaglutida y cuándo tirzepatida?
La EASO acaba de actualizar su algoritmo con evidencia hasta noviembre 2025 📊 @EASOobesity

Spoiler: depende del objetivo clínico. No es solo pérdida de peso.

🔗 @NatureMedicine

https://t.co/RKkccNGYTq

#ECO2026

[Dr Amar Puttanna 🎸 @AmarPut]

Interesting data from #ECO2026 @EASOobesity
Building on the need for more data in women’s health esp around menopause but more interesting is the migraine data

Expanding the other potential beneficial effects of weight loss and why there are also trials in IIH with incretins

[Kevin Fernando @drkevinfernando]

🔥My latest Medscape Primary Care #Hack is live!

💡Continuous Glucose Monitoring #CGM for people living with #T2D

Co-authored with @drheatherbell

Includes 8 simple steps to interpreting the Ambulatory Glucose Profile report #AGP

PDF download link in comments 👇

[Partha S Kar 🇮🇳🇬🇧🏏🎥 @parthaskar]

Don’t miss the signs of #T1Diabetes

The 4 Ts

And no, they don’t have to be altogether as a presentation

Keep this in your mind as a possible diagnosis

Even one life saved?
Is worth all the “cost”

Better safe than sorry

#T1Diabetes 💙

[GoggleDocs @GoggleDocs]

@Andy_Ross1962 @TheMeldrew lots of noise coming from the airport, although nothing on flightradar 24

[Dr Amar Puttanna 🎸 @AmarPut]

Check out our latest @GoggleDocs NICE summary - Semaglutide 2.4mg in ASCVD

@DrDerekConnolly @escardio @ATTDconf @EASDelearning @banshisaboo @dramitaol @AskDrShashank @hvanspall @BrJCardiol @ABCDiab @NICEComms

[Neil Floch MD @NeilFlochMD]

So folks: this means that if you have obesity…. You are 38% less likely to die if you have bariatric surgery - there are no studies for GLP-1ra that show these dramatic results.

[GoggleDocs @GoggleDocs]

🚨NICE TA1152: #semaglutide 2.4 mg recommended as an option for ⤵️💔risk in adults with established CVD and BMI ≥27 kg/m² 🚨

🔹 Eligible: previous MI, ischaemic/haemorrhagic stroke, or symptomatic PAD, with BMI ≥27. No restriction on time since index event. T2D not excluded.

🔸 SELECT (n=17,604): First MACE: HR 0.80 (0.72-0.90) Non-fatal MI: HR 0.72 (0.61-0.85) Coronary revasc: HR 0.77 (0.68-0.87) All-cause death: HR 0.81 (0.71-0.93) Benefit appeared early, before substantial weight loss.

🔹 Preferred ICERs £6,878 to £14,594 per QALY, well below the £20,000 threshold.

🔸 What a TA means for access: statutory funding mandate. ICBs in England must make it available within 90 days when considered the right treatment (Wales: 60 days from final draft). But that doesn't mean immediate primary care prescribing.

🔗 https://t.co/WRVJ0F8gOB
#PrimaryCare #Cardiology #GLP1 #NICE

[funf.studio @radartabs]

Nigel Farage literally wrote the book on this…